2025-11-04

Q3 2025 Results

2025-08-05

Q2 2025 Results

Revenue and EPS data not available in provided content

2025-05-05

Q1 2025 Results

Financial data not accessible in provided format

2024-11-04

Q3 2024 Results

2024-08-05

Q2 2024 Results

2024-05-08

Q1 2024 Results

2025-02-27

FY 2024 Results

📌 Completed acquisition of Seagen in December 2023, with full-year 2024 integration and operations including oncology portfolio expansion

2024-02-22

FY2023 2023 Results

📌 Completed acquisition of Seagen on December 14, 2023, adding significant oncology capabilities to Pfizer's pipeline

2025-11-21

Debt Offering

$5B multi-tranche notes, rates 3.875%-5.7%

2025-11-13

Acquired Metsera

$7.0B enterprise value, up to $20.65/share contingent payments

2025-11-04

Q3 2025 Earnings

Q3 2025 financial results announced

2025-08-05

Q2 2025 Earnings

Q2 2025 financial results announced

2025-05-19

Euro Debt Offering

€3.3B notes issued: 2.875%-4.25% rates, 2029-2045 maturities

2025-04-29

Q1 Earnings & $1.2B Cost Savings Program

$1.2B additional savings by 2027, $1.6B implementation costs

2025-04-28

Annual Shareholder Meeting

13 directors elected, auditor ratified, exec comp approved, 2 shareholder proposals rejected

2025-02-04

Q4 2024 Earnings

Q4 and full-year 2024 financial results announced

2024-12-17

2025 Guidance Issued

Full-year 2025 guidance provided, 2024 guidance reaffirmed

2024-10-29

Q3 2024 Earnings

Q3 2024 financial results announced

2024-10-15

Board Director Election

Mortimer J. Buckley elected to Board

2024-07-30

Q2 2024 Earnings

Q2 2024 financial results announced

2024-07-26

Executive Compensation Plan Modifications

9,000 employees including 6 named executives get 2-year extensions on TSRUs and PSAs

2024-07-10

CSO Departure Announced

Dr. Mikael Dolsten stepping down after 15+ years, successor search initiated

2024-07-01

Board Election

Cyrus Taraporevala elected to Board

2024-05-22

Cost Reduction Program Launch

$1.5B savings by 2027, $1.7B one-time costs

2024-05-01

Q1 2024 Earnings

Q1 2024 financial results announced

2024-04-29

Annual Shareholder Meeting

All 12 directors elected, auditor ratified, executive comp approved

2024-01-30

Q4 2023 Earnings

Q4 and full-year 2023 financial results announced

2024-01-10

Mini-Tender Offer Received

TRC Capital offers $27.35/share for 4M shares, 4.4% below market